These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16979236)

  • 1. Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice.
    Vasconcelos FC; Cavalcanti GB; Silva KL; de Meis E; Kwee JK; Rumjanek VM; Maia RC
    Leuk Res; 2007 Apr; 31(4):445-54. PubMed ID: 16979236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
    Cavalcanti GB; Vasconcelos FC; Pinto de Faria G; Scheiner MA; de Almeida Dobbin J; Klumb CE; Maia RC
    Cytometry B Clin Cytom; 2004 Sep; 61(1):1-8. PubMed ID: 15351976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.
    Lamy T; Drenou B; Grulois I; Fardel O; Jacquelinet C; Goasguen J; Dauriac C; Amiot L; Bernard M; Fauchet R
    Leukemia; 1995 Sep; 9(9):1549-55. PubMed ID: 7658724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.
    Vasconcelos FC; Silva KL; Souza PS; Silva LF; Moellmann-Coelho A; Klumb CE; Maia RC
    Cytometry B Clin Cytom; 2011 May; 80(3):158-66. PubMed ID: 21520403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Kolodziej B; Rafinska B; Kubicka M; Koltan S; Koltan A; Pogorzala M; Kurylak A; Olszewska-Slonina D; Balwierz W; Juraszewska E; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Malinowska I; Stanczak E; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Maciejka-Kapuscinska L
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):875-93. PubMed ID: 17671794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
    Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
    Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.
    Ascione A; Cianfriglia M; Dupuis ML; Mallano A; Sau A; Pellizzari Tregno F; Pezzola S; Caccuri AM
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):419-24. PubMed ID: 19288261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation.
    Park SH; Park CJ; Kim DY; Lee BR; Kim YJ; Cho YU; Jang S
    Leuk Res; 2015 Oct; 39(10):1109-16. PubMed ID: 26248945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effect of phenothiazines on MRP1 and P-glycoprotein activity.
    Wesołowska O; Molnar J; Ocsovszki I; Michalak K
    In Vivo; 2009; 23(6):943-7. PubMed ID: 20023237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
    Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
    Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.
    Maia RC; Carriço MK; Klumb CE; Noronha H; Coelho AM; Vasconcelos FC; Ruimanek VM
    J Exp Clin Cancer Res; 1997 Dec; 16(4):419-24. PubMed ID: 9505216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
    Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
    Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia.
    Swerts K; de Moerloose B; Dhooge C; Noens L; Laureys G; Benoit Y; Philippé J
    Leuk Lymphoma; 2004 Nov; 45(11):2221-8. PubMed ID: 15512810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups.
    Legrand O; Zompi S; Perrot JY; Faussat AM; Benderra Z; Chaoui D; Marie JP
    Haematologica; 2004 Jan; 89(1):34-41. PubMed ID: 14754604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.
    Minderman H; Vanhoefer U; Toth K; Yin MB; Minderman MD; Wrzosek C; Slovak ML; Rustum YM
    Cytometry; 1996 Sep; 25(1):14-20. PubMed ID: 8875050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.
    Broxterman HJ; Sonneveld P; Feller N; Ossenkoppele GJ; Währer DC; Eekman CA; Schoester M; Lankelma J; Pinedo HM; Löwenberg B; Schuurhuis GJ
    Blood; 1996 Jun; 87(11):4809-16. PubMed ID: 8639853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia.
    Fujimaki S; Funato T; Harigae H; Fujiwara J; Kameoka J; Meguro K; Kaku M; Sasaki T
    Clin Chem; 2002 Jun; 48(6 Pt 1):811-7. PubMed ID: 12028995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines.
    Dogan AL; Legrand O; Faussat AM; Perrot JY; Marie JP
    Leuk Res; 2004 Jun; 28(6):619-22. PubMed ID: 15120939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications.
    da Silveira Júnior LS; Soares VL; Jardim da Silva AS; Gil EA; Pereira de Araújo MDG; Merces Gonçalves CA; Paiva AS; Moura de Oliveira TM; Oliveira GHM; Kramer Cavacanti E Silva DG; de Araújo Moura Lemos TM; Moretti Rebecchi IM; de Farias Sales VS; Luchessi AD; Cavalcanti Júnior GB
    Int J Lab Hematol; 2020 Oct; 42(5):594-603. PubMed ID: 32452631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients.
    Mahjoubi F; Akbari S; Montazeri M; Moshyri F
    Genet Mol Res; 2008; 7(4):1369-74. PubMed ID: 19065772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.